Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Paclitaxel + Telmisartan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Telmisartan | BIBR 277|Micardis | Telmisartan is a AT1R antagonist that also acts as a PPARG agonist to inhibit IL-6 expression, potentially resulting in decreased tumor cell proliferation (PMID: 39032472). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06815497 | Phase II | Docetaxel + Telmisartan Paclitaxel + Telmisartan Nab-paclitaxel + Telmisartan Doxorubicin + Telmisartan Pegylated liposomal doxorubicin + Telmisartan | Telmisartan in Combination with Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer | Not yet recruiting | USA | 0 |